Errata

The May 10, 2018, editorial by Kolesar et al entitled “Low-Fat Abiraterone Food Effect Is of Little Consequence” (*J Clin Oncol* 10.1200/JCO.2018.78.0684) was published with errors.

In the Authors’ Disclosures of Potential Conflicts of Interest section, Glenn Liu’s disclosures read as:

Glenn X. Liu

Leadership: AIQ Solutions

Stock or Other Ownership: AIQ Solutions

Research Funding: Johnson & Johnson (Inst), Novartis (Inst), Madison Vaccines, Pfizer, TRACON Pharmaceuticals

Patents, Royalties, Other Intellectual Property: US 9161720 B2: Quantitative evaluation of total tumor burden using functional and anatomical imaging (Inst)

They should have read as:

Glenn Liu

Leadership: AIQ Solutions

Stock or Other Ownership: AIQ Solutions

Consulting or Advisory Role: Janssen, Exelixis, Novartis

Research Funding: Johnson & Johnson (Inst), Novartis (Inst), Madison Vaccines, Pfizer, TRACON Pharmaceuticals

Patents, Royalties, Other Intellectual Property: US 9161720

B2: Quantitative evaluation of total tumor burden using functional and anatomical imaging (Inst)

Other Relationship: Sanofi

This has been corrected as of November 6, 2018. The authors apologize for these errors.

DOI: <https://doi.org/10.1200/JCO.18.01671>; published December 1, 2018

The September 6, 2018, correspondence by Kolesar et al entitled “Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al” (*J Clin Oncol* 10.1200/JCO.2018.79.3208) was published with errors.

PSA PFS (8.6 mo) as reported by Szmulewitz and colleagues (Reference 10) was inadvertently compared with radiographic PFS (16.5 mo) from the Ryan manuscript (Reference 4).

The fourth sentence of the second paragraph read as: As we discussed previously, although progression-free survival was similar between the doses at 8.6 months, it was inferior when compared with the landmark study at 16.5 months.

This should have read as: As we discussed previously, although progression-free survival was similar between the doses at 8.6 months, it was inferior when compared with the landmark study at 11.1 months.

The authors did not mean to imply that food-effect trials are unimportant, or that the trial was poorly conducted. They congratulate the authors for conducting this trial and believe that additional studies to validate these interesting results are needed before adoption in clinical practice can be recommended.

In the Authors’ Disclosures of Potential Conflicts of Interest section, Glenn Liu’s disclosures read as:

Glenn Liu

Leadership: AIQ Solutions

Stock or Other Ownership: AIQ Solutions

Research Funding: Company: Johnson & Johnson (Inst),

Novartis (Inst), Madison Vaccines, Pfizer, TRACON Pharma

Patents, Royalties, Other Intellectual Property: US 9161720

B2: Quantitative evaluation of total tumor burden using functional and anatomic imaging (Inst)

They should have read as:

Glenn Liu

Leadership: AIQ Solutions

Stock or Other Ownership: AIQ Solutions

Consulting or Advisory Role: Janssen, Exelixis, Novartis

Research Funding: Johnson & Johnson (Inst), Novartis (Inst), Madison Vaccines, Pfizer, TRACON Pharmaceuticals

Patents, Royalties, Other Intellectual Property: US 9161720

B2: Quantitative evaluation of total tumor burden using functional and anatomical imaging (Inst)

Other Relationship: Sanofi

This has been corrected as of November 6, 2018. The authors apologize for these errors.

DOI: <https://doi.org/10.1200/JCO.18.01672>; published December 1, 2018